Cost-effectiveness and budget impact of lopinavir/ritonavir and atazanavir plus ritonavir regimens based on 48-week results from the CASTLE study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-2652
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Cost-effectiveness and budget impact of lopinavir/ritonavir and atazanavir plus ritonavir regimens based on 48-week results from the CASTLE study ; volume:11 ; number:1 ; day:10 ; month:11 ; year:2008 ; pages:1 ; date:12.2008
Journal of the International AIDS Society / International AIDS Society ; 11, Heft 1 (10.11.2008), 1, 12.2008
- Creator
-
Simpson, KN
- Contributor
-
Rajagopalan, R.
Dietz, B.
SpringerLink (Online service)
- DOI
-
10.1186/1758-2652-11-S1-P311
- URN
-
urn:nbn:de:1111-2016052053997
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:02 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Simpson, KN
- Rajagopalan, R.
- Dietz, B.
- SpringerLink (Online service)
Other Objects (12)
Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
Metabolic: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir
Nirmatrelvir Plus Ritonavir: First Approval
Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir
Lopinavir/ritonavir monotherapy in clinical practice
Scutellaria baicalensis decreases ritonavir-induced nausea
Lipometabolic side-effects of three ritonavir-boosted double protease inhibitor regimens without reverse transcriptase inhibitors
Pharmakokinetik der Protease-Inhibitoren Lopinavir und Ritonavir
Correction to: Nirmatrelvir Plus Ritonavir: First Approval
Minority M184V variants in women exposed to 3TC/FTC-containing lopinavir-ritonavir (LPVr) regimens in pregnancy
Ombitasvir/Paritaprevir/Ritonavir: Nutzenbewertung gemäß § 35a SGB V
Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
Metabolic: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir
Nirmatrelvir Plus Ritonavir: First Approval
Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir
Lopinavir/ritonavir monotherapy in clinical practice
Scutellaria baicalensis decreases ritonavir-induced nausea
Lipometabolic side-effects of three ritonavir-boosted double protease inhibitor regimens without reverse transcriptase inhibitors
Pharmakokinetik der Protease-Inhibitoren Lopinavir und Ritonavir
Correction to: Nirmatrelvir Plus Ritonavir: First Approval
Minority M184V variants in women exposed to 3TC/FTC-containing lopinavir-ritonavir (LPVr) regimens in pregnancy
Ombitasvir/Paritaprevir/Ritonavir: Nutzenbewertung gemäß § 35a SGB V
Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
Metabolic: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir
Nirmatrelvir Plus Ritonavir: First Approval
Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir
Lopinavir/ritonavir monotherapy in clinical practice
Scutellaria baicalensis decreases ritonavir-induced nausea
Lipometabolic side-effects of three ritonavir-boosted double protease inhibitor regimens without reverse transcriptase inhibitors
Pharmakokinetik der Protease-Inhibitoren Lopinavir und Ritonavir
Correction to: Nirmatrelvir Plus Ritonavir: First Approval
Minority M184V variants in women exposed to 3TC/FTC-containing lopinavir-ritonavir (LPVr) regimens in pregnancy